Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

The new biotech SpringWorks has spun out of Pfizer on a mission to develop four badly-needed drugs for rare and serious diseases.

Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat ...

Find the latest on short interest, settlement dates, average share volume, and days to cover for SpringWorks Therapeutics, Inc. Common Stock (SWTX) at Nasdaq.com.

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on ...

See the latest Merck KGaA ADR stock price (MKKGY:PINX), related news, valuation, dividends and more to help you make your investing decisions.

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.